SARS‐CoV‐2–host proteome interactions for antiviral drug discovery

SARS‐CoV‐2–host proteome interactions for antiviral drug discovery

Abstract Treatment options for COVID‐19, caused by SARS‐CoV‐2, remain limited. Understanding viral pathogenesis at the molecular level is critical to develop effective therapy. Some recent studies have explored SARS‐CoV‐2–host interactomes and provided great resources for understanding viral replica...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Xiaonan Liu, Sini Huuskonen, Tuomo Laitinen, Taras Redchuk, Mariia Bogacheva, Kari Salokas, Ina Pöhner, Tiina Öhman, Arun Kumar Tonduru, Antti Hassinen, Lisa Gawriyski, Salla Keskitalo, Maria K Vartiainen, Vilja Pietiäinen, Antti Poso, Markku Varjosalo
Formato: article
Lenguaje:EN
Publicado: Wiley 2021
Materias:
drug discovery
mass spectrometry
proteomics
SARS‐CoV‐2
virus–host interactions
Biology (General)
QH301-705.5
Medicine (General)
R5-920
Acceso en línea:https://doaj.org/article/c87ddbd7671244cc9c1ca8b5b5555d62
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/c87ddbd7671244cc9c1ca8b5b5555d62

Ejemplares similares